FDA Approval and Intended Use Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are specifically FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition
Consequently, information found in the general public realm is not subject to patent protection (Gonzalez-Fierro and Duenas-Gonzalez 2019)
The Clinical Consequences: Beyond the Scale Unchecked nutrient deficits can subtly erode multiple systems, ultimately undermining the benefits of GLP-1 therapy
Why it matters: A number without monitoring rules can be misleading
Start your intake How Semaglutide Affects Digestive Health and IBS Semaglutide works by activating GLP-1 receptors in the gut and brain, which delays how quickly food moves through your stomach and into the small intestine
Daily exercise like walking, dancing, cycling, or swimming can help you get higher-quality sleep at night